Synopsis: Navin Fluorine International reported a strong FY26 performance with revenue rising 41 percent and net profit jumping 130 percent, supported by robust growth across specialty chemicals, refrigerants, and its rapidly expanding CDMO business.
India’s fluorochemicals and pharmaceutical outsourcing sectors are witnessing structural growth as global manufacturers diversify supply chains beyond China and seek reliable, cost-efficient partners. This trend is creating significant opportunities for companies with advanced chemistry capabilities and strong regulatory compliance.
Shares of Navin Fluorine International Ltd, with a market capitalization of Rs. 39,251.33 crore, are trading at a price of Rs. 7,655.00, up 0.49% from its previous closing price of Rs. 7,618.00. The stock touched an intraday high of Rs. 7,710.00 and a low of Rs. 7,620.00. It is trading at a P/E ratio of 58.87.
What’s the News?
Navin Fluorine International has filed its first Integrated Annual Report for FY26 along with the notice for its 28th Annual General Meeting, scheduled to be held through video conferencing on August 6, 2026, in compliance with SEBI listing regulations.
The board has recommended a final dividend of Rs. 8.60 per equity share having a face value of Rs. 2. The payment is expected on or after August 13, 2026, while shareholders eligible as of the June 12, 2026 record date will receive the dividend.
The annual report also marks the company’s transition towards integrated reporting standards aligned with the IFRS Foundation framework, GRI Standards and TCFD recommendations, reflecting increasing emphasis on sustainability and enhanced corporate disclosures.
Financial & Business Analysis
Navin Fluorine delivered six consecutive quarters of revenue and profit growth during FY26. Consolidated revenue from operations increased by 41.05 percent year-on-year to Rs. 3,313.90 crore, while operating EBITDA surged by 102.67 percent to Rs. 1,081.68 crore.
Profitability improved sharply during the year. EBITDA margin expanded by 992 basis points to 32.64 percent, while net profit margin rose to 20.02 percent as newly commissioned capacities ramped up and the company benefited from improved product mix and better realisations.
Net profit more than doubled to Rs. 663.55 crore compared to the previous year, translating into earnings per share of Rs. 130.67. Return on Capital Employed improved to 25.92 percent, while Return on Equity increased to 20.11 percent, indicating significantly stronger capital efficiency.
The company’s balance sheet remained robust despite substantial expansion initiatives. Operating cash flows rose to Rs. 893.57 crore from Rs. 570.81 crore in FY25, while net debt-to-equity remained negligible at 0.01, supported by a Rs. 750 crore Qualified Institutional Placement completed during the year.
Quarterly momentum remained strong entering FY27. Revenue during Q4 FY26 increased by 34 percent to Rs. 937.71 crore, while EBITDA rose 80 percent to Rs. 321.15 crore. Net profit jumped 124 percent year-on-year to Rs. 212.62 crore.
Segment-wise, High Performance Products generated revenue of Rs. 1,615.38 crore, growing 33.93 percent. Specialty Chemicals revenue increased by 43.94 percent to Rs. 1,152.09 crore, while the CDMO business emerged as the fastest-growing vertical with revenue rising 59.39 percent to Rs. 546.43 crore.
The sharp growth in CDMO operations significantly improves earnings visibility, as pharmaceutical outsourcing contracts generally provide longer-term revenue streams and stronger margins. Continued capacity additions also position the company to monetise recent investments over the coming years.
Industry & Strategic Analysis
Navin Fluorine has undertaken a broad-based capex programme across all its business segments. During FY26, it commissioned a new hydrofluoric acid plant at Dahej and approved Rs. 236.50 crore for additional R32-equivalent refrigerant capacity of up to 15,000 MTPA.
The company has also committed Rs. 75 crore towards debottlenecking its multipurpose plant and another Rs. 120 crore towards manufacturing immersion cooling fluids under Chemours’ Opteon brand. This project targets the rapidly expanding data centre and artificial intelligence infrastructure ecosystem.
The partnership with Chemours could represent a significant strategic milestone for Navin Fluorine, allowing the company to enter advanced materials and data-centre cooling applications, which are expected to benefit from long-term global demand growth driven by AI adoption.
The CDMO segment continues to gain traction, particularly in European markets. Commercial supplies from the cGMP4 Phase-I facility at Dewas commenced during FY26, while management commentary indicates further pipeline opportunities that could sustain above-industry growth rates.
The company also remains highly export-oriented, generating export revenue of Rs. 2,225.40 crore compared to domestic revenue of Rs. 1,088.50 crore. CDMO exports accounted for over 96 percent of segment revenue, providing significant global exposure but also increasing sensitivity to international demand cycles.
Total capital expenditure during FY26 stood at Rs. 489.26 crore, lower than the peak spending levels seen in the previous two years. This indicates that Navin Fluorine may be entering a phase of capacity monetisation, potentially improving free cash generation and return ratios.
Company Overview
Navin Fluorine International Limited, part of the Padmanabh Mafatlal Group, is among India’s leading integrated fluorochemical manufacturers. The company operates across High Performance Products, Specialty Chemicals and Contract Development and Manufacturing Organisation (CDMO) businesses, with manufacturing facilities located in Surat, Dahej, Dewas and Manchester, United Kingdom.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
